NYSE:JNJPharmaceuticals
Johnson & Johnson Oncology Advances Inform Multiple Myeloma Growth Outlook
FDA approved a new DARZALEX FASPRO combination regimen for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant, marking the drug’s twelfth indication.
New Phase 3 data for TECVAYLI in relapsed or refractory multiple myeloma showed significant progression free and overall survival benefits in hard to treat patients.
The updates expand Johnson & Johnson’s oncology portfolio within its pharmaceutical and MedTech businesses.
For investors watching Johnson &...